These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 15127424)

  • 41. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
    Charlton V
    J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 10 Years of End-of-Life Criteria in the United Kingdom.
    Bovenberg J; Penton H; Buyukkaramikli N
    Value Health; 2021 May; 24(5):691-698. PubMed ID: 33933238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can the NICE "end-of-life premium" be given a coherent ethical justification?
    Cookson R
    J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prioritizing health technologies in a Primary Care Trust.
    Wilson E; Sussex J; Macleod C; Fordham R
    J Health Serv Res Policy; 2007 Apr; 12(2):80-5. PubMed ID: 17407656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?
    Walley T
    CNS Drugs; 2004; 18(1):1-12. PubMed ID: 14731055
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).
    George B; Harris A; Mitchell A
    Pharmacoeconomics; 2001; 19(11):1103-9. PubMed ID: 11735677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accounting for inflation within NICE cost-effectiveness thresholds.
    Low V; Macaulay R
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):131-137. PubMed ID: 33980118
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?
    Claxton K; Sculpher M; Palmer S; Culyer AJ
    Health Econ; 2015 Jan; 24(1):1-7. PubMed ID: 25488707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is the QALY blind, deaf and dumb to equity? NICE's considerations over equity.
    Soares MO
    Br Med Bull; 2012; 101():17-31. PubMed ID: 22331197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimating 'costs' for cost-effectiveness analysis.
    Miners A
    Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant.
    Dowie J
    Health Econ; 2004 May; 13(5):453-9. PubMed ID: 15127425
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fair Funding Decisions: Consistency of the Time Horizons Used in the Calculation of Quality-Adjusted Life Years for Therapies for Very Rare Diseases by the National Institute for Health and Care Excellence in England.
    Barman-Aksözen J; Hentschel N; Pettersson M; Schupp E; Granata F; Dechant C; Aksözen MH; Falchetto R
    Int J Environ Res Public Health; 2024 May; 21(5):. PubMed ID: 38791830
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding the National Institute for Health and Care Excellence Severity Premium: Exploring Its Implementation and the Implications for Decision Making and Patient Access.
    Njoroge MW; Walton M; Hodgson R
    Value Health; 2024 Jun; 27(6):730-736. PubMed ID: 38447743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
    Paulden M
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):239-242. PubMed ID: 28490259
    [No Abstract]   [Full Text] [Related]  

  • 55. Cost-effective public health guidance: asking questions from the decision-maker's viewpoint.
    Chalkidou K; Culyer A; Naidoo B; Littlejohns P
    Health Econ; 2008 Mar; 17(3):441-8. PubMed ID: 17764094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
    Kaltenthaler E; Papaioannou D; Boland A; Dickson R
    Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is there a kink in consumers' threshold value for cost-effectiveness in health care?
    O'Brien BJ; Gertsen K; Willan AR; Faulkner LA
    Health Econ; 2002 Mar; 11(2):175-80. PubMed ID: 11921315
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
    Charlton V
    Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.